The Latest Breaking News from Humira

We have all seen them time and time again: the overly cheerful people jogging through parks, painting fences, or laughing over salads while a voice calmly lists horrifying side effects like “possible internal bleeding” and “sudden death.” Drug commercials are a strange blend of optimism and danger, and sometimes they…

Here are five “set-and-forget” dividend stocks.

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

CHICAGO — One of the most popular prescription medications in the world is about to face fierce competition in the U.S. — something that could mean lower prices for the drug but a difficult coming year for the Illinois company that makes it.

Cigna Corp (NYSE: CI) is poised to benefit from the launch of bioequivalent Humira in July 2023, according to Morgan Stanley.

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

Here's a roundup of top developments in the biotech space over the last 24 hours.